++
Section 14: Hematologic Disorders
++
++
++
The genetic inheritance pattern for hemophilia is:
++
++
++
++
++
++
++
++
++
+
+
++
++
++
The factor deficit in hemophilia B is:
++
++
++
++
++
++
++
++
++
+
+
++
++
++
Which of the following is not considered a goal of Hemophilia therapy?
++
++
++
A. Prevent bleeding episodes
++
++
B. Prevent long term complications
++
++
++
++
D. Arrest bleeding if it occurs
+
+
++
++
++
Patients with severe hemophilia have ______% factor activity level.
++
++
++
++
++
++
++
++
++
+
+
++
++
++
The first-line therapeutic approach to treating an active bleed in a patient with severe hemophilia without inhibitors is:
++
++
++
A. Plasma derived factor replacement
++
++
B. Recombinant factor replacement
++
++
C. Activated prothrombin complex concentrates (aPCCs)
++
++
++
++
+
+
++
++
++
Which is a true statement regarding prophylaxis therapy for hemophilia?
++
++
++
A. Not recommended by any national organization
++
++
B. Recommended approach but optimal dosing and schedule is not well defined
++
++
++
++
D. Patient compliance is not a factor in overall outcome
+
+
++
++
++
The most impactful therapeutic complication of therapy for hemophilia patients is:
++
++
++
++
++
++
++
++
++...